Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century, Int J Cardiol, vol.167, pp.1807-1831, 2013. ,
2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillationdeveloped with the special contribution of the European Heart Rhythm Association, Europace, vol.14, pp.1385-413, 2012. ,
AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, vol.64, pp.1-76, 2014. ,
The management of atrial fibrillation: summary of updated NICE guidance, BMJ, vol.348, p.3655, 2014. ,
focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation, Can J Cardiol, vol.30, pp.1114-1144, 2014. ,
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.141, pp.531-75, 2012. ,
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, vol.146, pp.857-67, 2007. ,
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis: Task Force on Anticoagulants in Heart Disease, Thromb Haemost, vol.109, pp.569-79, 2013. ,
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics, Ann Intern Med, vol.124, pp.970-979, 1996. ,
Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-51, 2009. ,
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, pp.883-91, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01038111
Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-92, 2011. ,
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, vol.383, pp.955-62, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00935589
Novel oral anticoagulants in non-valvular atrial fibrillation, Best Pract Res Clin Haematol, vol.26, pp.115-144, 2013. ,
Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation, J Intern Med, vol.278, pp.1-18, 2015. ,
Fibrillation auriculaire non valvulaire: Quelle place pour les anticoagulants oraux non antivitamine K:apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®, 2013. ,
Technical improvement of cohort constitution in administrative health databases: Providing a tool for integration and standardization of data applicable in the French National ,
, Rev Epidemiol Sante Publique, vol.64, pp.263-272, 2016.
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf, vol.26, pp.954-62, 2017. ,
Pharmacoepidemiological research using French reimbursement databases: yes we can!, Pharmacoepidemiol Drug Saf, vol.19, pp.256-65, 2010. ,
Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol, vol.30, pp.616-640, 2016. ,
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, pp.1093-100, 2010. ,
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, vol.137, pp.263-72, 2010. ,
National trends in oral anticoagulant use in the United States, Circ Cardiovasc Qual Outcomes, vol.5, pp.615-636, 2007. ,
National trends in ambulatory oral anticoagulant use, Am J Med, vol.128, pp.1300-1305, 2015. ,
Trends in the prescription of novel oral anticoagulants in UK primary care, Br J Clin Pharmacol, vol.83, pp.2096-106, 2017. ,
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation, J Am Heart Assoc, vol.2, p.535, 2013. ,
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, BMJ Open, vol.3, p.2758, 2013. ,
Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey, Am J Med, vol.127, pp.519-548, 2014. ,
Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: a population-based cohort study, Thromb Res, vol.140, pp.94-103, 2016. ,
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation-quality and cost implications, Am J Med, vol.127, pp.1075-82, 2014. ,
Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey, Europace, vol.17, pp.819-843, 2015. ,
Adoption of new drugs by physicians: a survival analysis, BMC Health Serv Res, vol.12, p.56, 2012. ,
New oral anticoagulants for nonvalvular atrial fibrillation in the elderly: limited applicability in primary care, Eur J Gen Pract, vol.21, pp.1-5, 2015. ,
Stroke prevention in atrial fibrillation: a systematic review, JAMA, vol.313, pp.1950-62, 2015. ,
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation, Pharmacoeconomics, vol.32, pp.601-613, 2014. ,
Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development, Clin Pharmacol Ther, vol.90, pp.777-90, 2011. ,
, Xarelto (rivaroxaban): mise en garde sur les facteurs de risques hémorragiques -Lettre aux professionnels de santé, Agence Nationale de Sécurité du Médicament et des produits de santé. Nouveaux anticoagulants oraux Eliquis (apixaban), Pradaxa (dabigatran), 2013.
Les anticoagulants oraux antivitamine K restent la référence dans la fibrillation auriculaire non valvulaireCommuniqué de presse, 2013. ,
Point sur l'utilisation des nouveaux anticoagulants oraux -Communiqué de Presse, 2013. ,
Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, Rev Epidemiol Sante Publique, vol.65, issue.4, pp.149-167, 2017. ,